Literature DB >> 16098137

Therapeutic implications of the mGluR theory of fragile X mental retardation.

M F Bear1.   

Abstract

Evidence is reviewed that the consequences of group 1 metabotropic glutamate receptor (Gp1 mGluR) activation are exaggerated in the absence of the fragile X mental retardation protein, likely reflecting altered dendritic protein synthesis. Abnormal mGluR signaling could be responsible for remarkably diverse psychiatric and neurological symptoms in fragile X syndrome, including delayed cognitive development, seizures, anxiety, movement disorders and obesity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098137     DOI: 10.1111/j.1601-183X.2005.00135.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  65 in total

1.  Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.

Authors:  Laura K K Pacey; Sujeenthar Tharmalingam; David R Hampson
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

2.  Homeostatic scaling requires group I mGluR activation mediated by Homer1a.

Authors:  Jia-Hua Hu; Joo Min Park; Sungjin Park; Bo Xiao; Marlin H Dehoff; Sangmok Kim; Takashi Hayashi; Martin K Schwarz; Richard L Huganir; Peter H Seeburg; David J Linden; Paul F Worley
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

Review 3.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

4.  Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists.

Authors:  Santosh S Kulkarni; Amy Hauck Newman
Journal:  Bioorg Med Chem Lett       Date:  2007-01-04       Impact factor: 2.823

Review 5.  Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Faqi Li
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

6.  Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists.

Authors:  Santosh S Kulkarni; Amy Hauck Newman
Journal:  Bioorg Med Chem Lett       Date:  2007-03-24       Impact factor: 2.823

7.  Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.

Authors:  Santosh S Kulkarni; Mu-Fa Zou; Jianjing Cao; Jeffrey R Deschamps; Alice L Rodriguez; P Jeffrey Conn; Amy Hauck Newman
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

Review 8.  The fragile X mental retardation protein in circadian rhythmicity and memory consolidation.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Mol Neurobiol       Date:  2009-02-12       Impact factor: 5.590

Review 9.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

10.  Open-label memantine in fragile X syndrome.

Authors:  Craig A Erickson; Jennifer E Mullett; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.